NCT00124930终止3 期
A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Severity of nausea on days 3 and 5
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
详细描述
The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>18 years of age
- •Significant nausea/vomiting
- •Failed maxeran and domperidone
- •Underlying treatment of causes has failed
- •Adequate cognitive function
- •Communicates well
排除标准
- •Partial/complete bowel obstruction
- •Currently taking Haldol or olanzapine
- •Has drug induced extrapyramidal symptoms
- •Parkinson's disease
- •Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus
结局指标
主要结局
Severity of nausea on days 3 and 5
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaSchizophreniaNCT00485901Eli Lilly and Company50
已完成
4 期
Study of Olanzapine vs. Aripiprazole in the Treatment of SchizophreniaSchizophreniaNCT00088049Eli Lilly and Company560
进行中（未招募）
2 期
Haloperidol and Lorazepam for Delirium in Patients With Advanced CancerAdvanced CancersNCT01949662M.D. Anderson Cancer Center93
已完成
3 期
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)OsteoarthritisNCT00092352Merck Sharp & Dohme LLC395
已完成
3 期
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)OsteoarthritisNCT00092365Merck Sharp & Dohme LLC413